MetaCap

Novartis AG Company Profile

NYSE: NVSHealth CareBiotechnology: Pharmaceutical PreparationsUSD

150.47-0.75 (-0.50%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

Novartis at a glance

Novartis AG (NYSE: NVS) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in Basel, Switzerland. Novartis is led by Dr. Vasant Narasimhan M.D. and employs about 75,267 people. At a market capitalization of $288.61 billion, it ranks among the largest companies in the US market.

Its SEC Central Index Key (CIK) is 0001114448, which identifies the company's filings on EDGAR.

Summary generated from market data by MetaCap's automated system. Methodology

What does Novartis do?

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure; Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6; Promacta/Revolade for immune thrombocytopenia (ITP), thrombocytopenia, and aplastic anemia patients; Tafinlar+Mekinist, an oral combination therapy to treat cancer patients; and Jakavi for treating myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease. It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in chronic and/or accelerated phase; Xolair for treating allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Stills disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma to treat genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran) to reduce LDL cholesterol. Novartis AG has a strategic alliance with CAS for enhancing reaction data accessibility and supporting AI-enabled research. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.

Business description based on the company's public filings.

Company information

Legal name
Novartis AG
Ticker
NYSE: NVS
Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Vasant Narasimhan M.D.
Employees
75,267
Headquarters
Lichtstrasse 35, Basel, Switzerland
Phone
41 61 324 11 11
Market cap
$288.61B
SEC CIK
0001114448

Companies similar to Novartis

NVS peer companies
CompanyPrice% ChgMarket capCompare
AZNAstraZeneca PLC174.35-0.60%$270.40Bvs NVS
MRKMerck & Company Inc.133.72+0.69%$329.65Bvs NVS
ABTAbbott Laboratories103.00-0.84%$178.39Bvs NVS
NVONovo Nordisk A/S37.82-2.70%$166.69Bvs NVS
PFEPfizer Inc.27.40-0.51%$156.18Bvs NVS
VRTXVertex Pharmaceuticals Incorporated515.02-1.08%$130.58Bvs NVS
BMYBristol-Myers Squibb Company58.80+0.79%$120.19Bvs NVS
SNYSanofi ADS46.52+1.00%$111.70Bvs NVS

Related